Aconitum Napellus Whole Fagopyrum Esculentum Whole
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Aconitum Napellus Whole Fagopyrum Esculentum Whole
- Complex Multi-Ingredient Homeopathic Formula: Insufficient Data for Repurposing Evaluation
Complex Multi-Ingredient Homeopathic Formula: Insufficient Data for Repurposing Evaluation
One-Sentence Summary
This product is a complex multi-ingredient formula composed of 15 botanical, homeopathic, and viral antigen components — including Aconitum napellus, multiple human herpesvirus antigens (HSV-1/2, VZV, EBV, CMV), and Glycyrrhiza glabra — with no registered indication on record. The TxGNN model could not generate any repurposing prediction for this compound, as no DrugBank ID could be matched for the mixture. There is no clinical trial or publication evidence linked to this formulation through the current pipeline.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Unknown — no licensed indication on record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — in this case, no prediction was generated) |
| US Market Status | Not marketed (未上市) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No TxGNN repurposing prediction was generated for this compound. The pipeline requires a valid DrugBank ID to anchor a candidate within the TxGNN knowledge graph; because this multi-ingredient formula lacks a DrugBank mapping, the model returned an empty result set.
The formula appears to be a homeopathic combination product. Its ingredients follow a classic homeopathic paradigm: Aconitum napellus (acute inflammatory states), Ranunculus bulbosus and Toxicodendron pubescens (dermatological and neuralgic symptoms), Sepia officinalis (hormonal/visceral complaints), and Solanum dulcamara (cold/damp aggravation). The inclusion of attenuated human herpesvirus antigens (HSV-1, HSV-2, VZV, EBV, CMV) and adenovirus antigen suggests the product may target viral or post-viral symptom complexes.
Because homeopathic combination products are formulated at ultra-dilute concentrations, conventional pharmacological mechanism-of-action analysis and knowledge-graph-based drug repurposing methods are not applicable without further characterisation of the active fractions. A repurposing evaluation would require reformulating the research question around individual bioactive components (e.g., glycyrrhizin from Glycyrrhiza glabra) rather than the mixture as a whole.
Safety Considerations
No safety data — including warnings, contraindications, or drug-drug interactions — were retrievable through the current pipeline for this formula. Individual ingredients carry known safety considerations that should be reviewed before any clinical application:
- Aconitum napellus contains aconitine alkaloids, which are cardiotoxic and neurotoxic at pharmacological doses.
- Toxicodendron pubescens contains urushiol, a potent contact allergen.
- Sodium hypochlorite is an oxidising agent with mucosal irritation potential.
Please refer to the product’s package insert and individual ingredient monographs for full safety information before any clinical use.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline could not evaluate this candidate because the multi-ingredient homeopathic formula has no DrugBank ID and no existing licensed indication, leaving the model without an entry point into the knowledge graph. Without a prediction, no repurposing hypothesis can be assessed.
To proceed, the following is needed:
- Identify whether any single active component (e.g., glycyrrhizin, aconite alkaloids) can be isolated as the primary repurposing candidate and mapped to a DrugBank node
- Clarify the regulatory classification of this product in its country of origin (homeopathic drug vs. biological vs. combination drug)
- Obtain the original manufacturer’s package insert to establish approved indications and safety profile
- If the antiviral antigen components are of primary interest, redirect the evaluation to the individual herpesvirus antigens or consider an immunological mechanism pathway separately from the botanical components
- Re-run the TxGNN pipeline against each decomposed active ingredient before attempting a combined evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.